Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2017 August;69(4) > Minerva Urologica e Nefrologica 2017 August;69(4):324-9



Publication history
Cite this article as


A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984




Minerva Urologica e Nefrologica 2017 August;69(4):324-9

DOI: 10.23736/S0393-2249.16.02623-0


language: English

Matrix metalloproteinase 9 and prostate cancer risk: a meta-analysis of 1059 participants

Fuling MA, Zhun WANG, Abdulalam ABDULARAB, Liang DAI, Yuanjie NIU, Ning JIANG

Department of Urology, Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China


INTRODUCTION: Numerous studies have evaluated the association between the matrix metalloproteinase 9 (MMP-9) and prostate cancer (PCa) risk. However, these studies have yielded conflicting results.
EVIDENCE ACQUISITION: A comprehensive search was conducted through researching MEDLINE, PubMed, Web of Science, and EMBASE, and a total of 10 studies including 1059 cases were included on the basis of inclusion criteria.
EVIDENCE SYNTHESIS: A meta-analysis was performed to obtain a summary of estimated odds ratios (ORs) and 95% confidence intervals (CIs) of MMP-9 for PCa, with attention to study quality and publication bias. MMP-9 by immunohistochemistry was significantly associated with increased diagnosis of PCa (OR=7.91; 95% CI: 5.27-11.89; P<0.00001). Subgroup-analysis showed that findings did not substantially change when only Caucasians or Asians (OR=5.87; 95% CI: 3.38-10.20; P<0.00001) or (OR=11.80; 95% CI: 6.60-21.08; P<0.00001) were considered. There was also no significant publication bias observed.
CONCLUSIONS: Our findings provide further evidence that the expression of MMP-9 contribute to PCa risk. MMP-9 protein overexpression was found in prostate cancers, low expression in any of the normal tissues or in benign prostatic tissue. MMP-9 is potentially an important prostate tumor marker.

KEY WORDS: Matrix metalloproteinase 9 - Prostatic neoplasms - Meta-analysis - Diagnosis - Biomarkers

top of page

Publication History

Issue published online: June 9, 2017
Article first published online: June 29, 2016
Manuscript accepted: June 26, 2016
Manuscript revised: June 7, 2016
Manuscript received: December 29, 2015

Cite this article as

Ma F, Wang Z, Abdularab A, Dai L, Niu Y, Jiang N. Matrix metalloproteinase 9 and prostate cancer risk: a meta-analysis of 1059 participants. Minerva Urol Nefrol 2017;69:324-9. DOI: 10.23736/S0393-2249.16.02623-0

Corresponding author e-mail